#Sepsis accounts for one in five deaths globally each year, yet doctors are largely in the dark when it comes to diagnosis and treatment. "From the clinician's perspective, treating septic patients is extremely challenging as you are trying to simultaneously manage the infection and the patient’s immune response, both highly dynamic. We need better #diagnostics that can rapidly inform treatment plans and support patient monitoring,” says Ephraim Tsalik, M.D., Ph.D, Chief Scientific Officer of Infectious Disease for Danaher Diagnostics businesses. Our Beacon collaboration with the University of Oxford leverages rapid molecular diagnostic technologies from Cepheid to pinpoint different sepsis subtypes and allow for the development of novel personalized care paths. "This work could ultimately make a difference for millions worldwide," says Vanessa Almendro, PhD, MBA ??, VP of Science and Technology Innovation at Danaher and head of our Beacons program. In recognition of World Sepsis Day, read about our Beacon for Sepsis Subtyping Innovation and why it has personal significance for Vanessa: https://lnkd.in/esdnVxSy ? #worldsepsisday #stopsepsis #speedoflife #precisionmedicine
关于我们
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond. For more information, visit www.danaher.com.
- 网站
-
https://www.danaher.com
Danaher Corporation的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 超过 10,001 人
- 总部
- Washington，District of Columbia
- 类型
- 上市公司
- 领域
- Life Sciences、Diagnostics和Biotechnology
地点
-
主要
获取路线
2200 Pennsylvania Ave NW
800 W
US，District of Columbia，Washington，20037
Danaher Corporation员工
动态
-
Some #breastcancer patients with low levels of the protein HER2 might be able to benefit from next-generation antibody drug conjugate targeted therapy—but we need a way to identify these patients effectively. Our newest Beacon collaboration with Yale University, the University of Pennsylvania and the Translational Breast Cancer Research Consortium (TBCRC) leverages cutting-edge technology from Leica Biosystems and Cepheid with the goal of improving #precisiondiagnostics for breast cancer patients expressing low levels of HER2. “Companion diagnostics are critical for ensuring the right medicines are prescribed to the right patients. We are thrilled to partner with David Rimm, Angela DeMichele MD, MSCE, FASCO and the entire team at the TBCRC to create a novel companion diagnostic to expand access to potentially lifesaving treatments for patients with invasive breast cancer,” said Rob Monroe, MD, PhD Vice President and Chief Scientific Officer at Leica Biosystems. https://lnkd.in/eJYbMs_t #speedoflife
-
-
Digitizing pathology has tremendous value, and layering on #AI gives us the capacity to analyze complex images more effectively than ever before. https://lnkd.in/eSKiyYbT
-
-
Yesterday our annual Investor and Analyst Meeting took place in Washington DC. Danaher Executive Vice President of Diagnostics Julie Sawyer Montgomery hosted the event, giving attendees insight into our differentiated #diagnostics positioning and how our businesses are working to transform #precisionmedicine. Watch the replay: https://bit.ly/3z8feO5
-
-
#Pathology is primed for a revolution. Digitization is key to ensuring we deliver the best information to providers and the best care to patients. https://lnkd.in/enF5fdRW
-
-
We're delighted to share our seventh annual #readinglist. For 2024, a time of rapid and dramatic change, we're focusing on classics and instant classics: five core curriculum books our leaders use to guide their long-term thinking and stay on track. Happy reading! https://bit.ly/3T4YJsS
-
-
#AI has made an impact on digital pathology. Now, how can we effectively accelerate #digitalpathology workflows to maximize their impact and enhance patient care? https://lnkd.in/ewjADKni
-
-
Cytiva?synthesizes findings from 800+ pharma and biopharma executives across 18 countries in their new Global?#Biopharma?#Sustainability?Review. TL;DR: Companies with a proven commitment to sustainability see benefits in revenue, profit, share price, brand reputation and talent attraction.?https://bit.ly/3XcHRmt
Making strides in sustainability is challenging. We surveyed 800 pharma and biopharma executives across 18 countries to learn more about the state of sustainability in biopharma. The Sustainability Review covers the industry’s sustainability progress in improving sustainability and the impact of prioritizing environmental initiatives. Dive into some of the findings here: https://cytiva.link/7fnal.
-
???????????????? ???????????????????????? We are proud to announce Genedata has joined Danaher Corporation, a leading global life sciences and diagnostics innovator. Over the past several years, Genedata and Danaher have engaged in several successful collaborations. Now, as a Danaher operating company, we expect to add to their broad workflow solutions that help accelerate drug discovery, development and manufacturing for critical new therapies. #speedoflife https://buff.ly/3MegMcl #Genedata #DanaherCorporation #LifeSciences #Innovation #Biopharma #DigitalizingBiopharma #GenedataDriven
-
-
We’re excited to share that Genedata, a leading provider of software solutions that digitalize and automate complex biopharma R&D processes, is joining Danaher. As a part of the Danaher Life Sciences segment, Genedata will further our efforts to accelerate the speed of drug discovery, development and manufacturing for critical new therapies. https://lnkd.in/eCdnii48
-